MedTrace Logo

Early Rheumatoid Arthritis COR Intervention

NCT02246257 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2022-05-23

No results posted yet for this study

Summary

The primary aim of our present study is to evaluate the effect of a targeted, intensified, multidimensional intervention compared to conventional treatment of modifiable risk factors for CVD in patients with early RA. The primary endpoint, a composite of death from cardiovascular causes, non-fatal MI, non-fatal stroke and re-vascularisation, will be assessed after 5years' follow-up.

Conditions

Interventions

OTHER

Simvastatin

LDL \> 2.5 is treated with 40 mg

OTHER

Losartan

BT \> 140/90 mmHg treated with 50 mg OD

OTHER

Losartan

DM BT \> 130/80 mmHg treated with 50 mg OD

OTHER

Losartan

Microalbuminuria (urinary albumin creatinin ratio \> 30 mg) treated with 100 mg OD

OTHER

Metformin

HBA1C \> 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks

OTHER

Outpatient rheumatology department

(4 times yearly)

OTHER

Refered to general practice

Sponsors & Collaborators

  • MD, PhD, Annemarie Lyng Svensson

    lead OTHER

Principal Investigators

  • Torkell J Ellingsen, MD, PhD · Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02246257 on ClinicalTrials.gov